Le Lézard
Classified in: Science and technology
Subject: Award

Online Dental Care Solution Dentistry.One Named a 2024 NJBIZ Health Care Hero


Dentistry.One, a virtual-first dental care solution introduced by MouthWatch, LLC, was recently named a 2024 Health Care Hero by leading New Jersey business publication, NJBIZ.

The annual award recognizes excellence, promotes innovation, and honors the efforts of the individuals and organizations making a significant impact on the quality of health care in New Jersey.

Candidates were nominated by NJBIZ reader submissions, with the winners selected by a panel of independent judges. This year's Health Care Heroes Awards recognized individuals and organizations across 11 categories. Dentistry.One was named a Health Care Hero in the "Innovation Hero" category.

"On behalf of the entire Dentistry.One team, we thank NJBIZ for this prestigious recognition of Dentistry.One and our commitment to developing innovative approaches that create greater access to oral healthcare," said Brant Herman, Founder & CEO, MouthWatch & Dentistry.One. "New Jersey has long been a pioneer in nurturing healthcare businesses impacting the health and well-being of individuals around the world. We are so proud to be part of this innovative and dynamic community."

Dentistry.One virtual-first oral health care offers access to a nationwide network of on-demand dentists, personalized care coordination, oral health coaching, and a digital connection between dental and medical care through proprietary teledentistry software.

Online dental consultations with Dentistry.One are accessible anytime, from anywhere and include services such as emergency care, pre-op and post-op support, non-narcotic e-prescriptions, second opinions, carries risk assessment, sleep apnea screening, oral hygiene instruction, chronic care coaching, and product recommendations.

About MouthWatch / Dentistry.One

MouthWatch, LLC, is a leader in developing digital technology solutions that drive success for dental professionals, improve oral health care, and enhance the overall patient experience.

Headquartered in Metuchen, New Jersey, MouthWatch is widely known for its intraoral cameras that help engage patients in treatment planning through high-quality, affordable imaging technology, and its TeleDent software that provides practices and organizations with a teledentistry option to engage patients with providers remotely.

In January of 2023, MouthWatch launched Dentistry.One, a virtual-first care network that addresses the expectations of today's modern healthcare consumers, the need for greater efficiency in healthcare, and the proven connection between good oral health and total health. Dentistry.One features on-demand dental consultations, personalized care coordination, and oral health coaching for prioritizing oral health.

MouthWatch hardware and software are in use at over 42,000 practices, over 30 leading Dental Service Organizations (DSOs), and over 100 dental schools. The company has been recognized three times in the Inc. 5000. For more information, visit mouthwatch.com. or dentistry.one.


These press releases may also interest you

at 06:13
eWTP Arabia Capital Technology Fund I ("Techology Fund I"), managed by eWTP Arabia Capital ("eWTPA"), one of the leading private equity firms in the Middle East, was listed in the Preqin League Tables as the the fifth top-performing VC funds in the...

18 mai 2024
Celltrion partners with TV star Mollie Pearce to launch the second installation of the Where's Crohn's & Colitis (CC)? campaign for this year's World IBD Day (19 May 2024). The campaign focuses on access to IBD care and treatment as the burden of...

18 mai 2024
The global industrial automation market in life sciences industry  size is estimated to grow by USD 5.06 bn from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of  11.4%  during the forecast period. ...

18 mai 2024
"Maximizing customer retention and expansion is more important than ever for B2B SaaS companies," said Steven Forth, CEO of Ibbaka. "Our...

18 mai 2024
Gilead Sciences, Inc. , following the recent acquisition of CymaBay Therapeutics, Inc., today announced interim results from the ongoing ASSURE study demonstrating treatment with seladelpar, an investigational PPAR delta agonist, led to improvements...

18 mai 2024
Mirum Pharmaceuticals, Inc. today announced data presented during the 56th European Society for Paediatric, Gastroenterology, Hepatology, and Nutrition (ESPGHAN) Annual Meeting which took place this week in Milan, Italy. Data from LIVMARLI®...



News published on and distributed by: